Business Context and Reporting Period
This Form 8-K filing by Tempest Therapeutics, Inc. (TPST) reports a corporate governance event dated July 12, 2021. The filing details the appointment of a new executive officer and the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation terms.
- Base Salary: $325,000 annually for the new Principal Financial Officer.
- Target Bonus: 30% of base salary.
- Equity Grant: Option to purchase 23,225 shares of common stock.
Material Changes
The primary material change is the appointment of Nicholas Maestas as Vice President, Strategy and Finance, and Principal Financial Officer, effective July 12, 2021. This appointment replaces the previous financial leadership structure, though the filing does not explicitly name a departing officer in this specific text.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, market outlook, or discussion of general business risks. The only contingencies disclosed relate to the executive's employment agreement:
- Termination without Cause/Good Reason (Standard): Entitles the officer to three months' base salary, earned bonuses, and three months of healthcare coverage.
- Termination without Cause/Good Reason (Change in Control): Entitles the officer to six months' base salary, 50% of the target bonus, six months of healthcare, and accelerated vesting of unvested equity awards.
Investor Verification Checklist
- Verify the vesting schedule for the 23,225 stock options (25% on July 12, 2022; remainder monthly over 48 months).
- Confirm the exercise price of the stock options, which is tied to the closing price on July 12, 2021.
- Review the Company's 2017 Equity Incentive Plan for details on future annual equity award eligibility.
- Check subsequent filings for any changes to the Company's liquidity position, as this 8-K does not report cash levels.